Jereme Sylvain Sells 3,638 Shares of DexCom (NASDAQ:DXCM) Stock

DexCom, Inc. (NASDAQ:DXCM) EVP Jereme Sylvain sold 3,638 shares of the company’s stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $83.27, for a total value of $302,936.26. Following the sale, the executive vice president owned 146,828 shares in the company, valued at approximately $12,226,367.56. The trade was a 2.42% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

DexCom Trading Up 2.1%

Shares of DXCM stock opened at $86.45 on Wednesday. The company has a market cap of $32.62 billion, a P/E ratio of 34.17, a PEG ratio of 1.42 and a beta of 1.42. The stock has a 50 day simple moving average of $83.25 and a two-hundred day simple moving average of $72.98. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.43 and a current ratio of 1.73. DexCom, Inc. has a fifty-two week low of $54.11 and a fifty-two week high of $92.59.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, July 30th. The medical device company reported $0.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.61 by $0.09. The firm had revenue of $1.31 billion for the quarter, compared to analysts’ expectations of $1.29 billion. DexCom had a return on equity of 35.94% and a net margin of 20.12%.The company’s revenue for the quarter was up 13.1% compared to the same quarter last year. During the same period in the prior year, the business earned $0.48 EPS. Research analysts forecast that DexCom, Inc. will post 2.64 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on DXCM shares. Deutsche Bank Aktiengesellschaft started coverage on shares of DexCom in a research note on Tuesday, June 23rd. They set a “buy” rating and a $86.00 target price on the stock. Robert W. Baird set a $105.00 price objective on shares of DexCom in a report on Friday, July 31st. Argus increased their price objective on shares of DexCom from $86.00 to $96.00 and gave the stock a “buy” rating in a research report on Tuesday, August 4th. Wall Street Zen upgraded DexCom from a “hold” rating to a “buy” rating in a research note on Sunday, September 6th. Finally, Mizuho upped their price target on DexCom from $90.00 to $95.00 and gave the stock an “outperform” rating in a research note on Friday, July 31st. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $88.71.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. Plato Investment Management Ltd bought a new stake in DexCom during the second quarter worth $782,000. Aurora Investment Counsel bought a new position in DexCom in the 2nd quarter valued at $2,340,000. E Fund Management Co. Ltd. purchased a new stake in shares of DexCom during the 2nd quarter valued at $1,273,000. Performance Wealth Partners LLC purchased a new stake in shares of DexCom during the 2nd quarter valued at $1,740,000. Finally, Silvant Capital Management LLC bought a new stake in shares of DexCom during the 2nd quarter worth $5,359,000. 97.75% of the stock is currently owned by institutional investors and hedge funds.

About DexCom

DexCom, Inc develops and commercializes continuous glucose monitoring (CGM) systems that measure glucose levels in real time. Its technology is designed to help people with diabetes monitor glucose trends and make more informed treatment and lifestyle decisions without relying solely on traditional fingerstick testing.

The company’s products include the Dexcom G7 and Dexcom G6 CGM systems, which use a small wearable sensor, transmitter or integrated sensor, and mobile applications to display glucose data.